Tipranks Press Release.
Motley Fool Press Release.
Detailed price information for Novocure Ltd Ord Sh (NVCR-Q) from The Globe and Mail including charting and trades.
BAAR, Switzerland, October 01, 2026--Novocure (Nasdaq: NVCR) will report financial results for the third quarter 2026 on October 29, 2026, before the U.S. financial markets open.
NovoCure has seen its share price move around in recent years, and the stock now trades at US$16.67, which raises a straightforward question for investors: Is that level supported by what the business is generating in sales today and what the market expects those sales to become over time? Over the past 5 years the share price has fallen 86.1%, which puts the current valuation debate squarely on whether the remaining market value still lines up with the revenue base. The business model...
NovoCure (NASDAQ:NVCR) outlined its strategy for returning its glioblastoma franchise to growth, expanding launches in pancreatic and lung cancer, and moving toward profitability during the Morgan Stanley Healthcare Conference. Chief Executive Officer Frank Leonard said the company, founded more th
NVCR says a cyber incident exposed limited patient and contact data, but devices stayed secure and operations remained fully functional.
BAAR, Switzerland, September 02, 2026--Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events.
NovoCure (NVCR) stock dips as the company discloses that a cybersecurity breach exposed limited patient and employee data. Read more here.
The average of price targets set by Wall Street analysts indicates a potential upside of 50.9% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
This is the newest page. Registered accounts read further back.